After exposure to alloantigen *in vivo*and *in vitro*, alloantigen reactive immunoregulatory activity is enriched in a population of CD4^+^T cells that express high levels of CD25, the α chain of the interleukin-2 receptor, and the transcription factor FOXP3. *In vivo*, common mechanisms underpin the activity of CD25^+^CD4^+^Treg in adult hosts. We identified a unique role for IFNγ in the functional activity of CD25^+^CD4^+^alloantigen reactive Treg during the development of operational tolerance to donor alloantigens *in vivo*that is consistent with observations showing that tolerance to alloantigens cannot be induced in the absence of IFNγ \[[@B1]\]. In order to provide proof of concept data for translation of findings in preclinical models to the bedside, we have demonstrated that human regulatory T cells expanded ex vivo can protect human allografts (skin and vessels) from rejection \[[@B2],[@B3]\].

The identification and characterisation of Treg that can control immune responsiveness to alloantigens has opened up exciting opportunities for new therapies in transplantation.
